Edition:
United States

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

25.40USD
16 Feb 2018
Change (% chg)

$0.75 (+3.04%)
Prev Close
$24.65
Open
$24.59
Day's High
$25.49
Day's Low
$24.51
Volume
57,120
Avg. Vol
75,245
52-wk High
$28.62
52-wk Low
$18.67

Latest Key Developments (Source: Significant Developments)

Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Xencor Inc ::XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS.XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018.  Full Article

Xencor posts Q3 loss of $0.33 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Xencor Inc :Xencor reports third quarter 2017 financial results and provides clinical pipeline update.Q3 revenue $7.1 million versus i/b/e/s view $6.3 million.Q3 loss per share $0.33.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Xencor Q2 loss per share $0.15
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Xencor Inc :Xencor reports second quarter 2017 financial results.Q2 revenue $13.3 million versus $66 million.Q2 revenue view $8.2 million -- Thomson Reuters I/B/E/S.Qtrly earnings per share loss $0.15.  Full Article

Xencor's lead drug candidate receives orphan drug designation from FDA
Thursday, 11 May 2017 08:00am EDT 

May 11 (Reuters) - Xencor Inc :Xencor's lead drug candidate, xmab5871, receives orphan drug designation from fda for treatment of igg4-related disease.  Full Article

Xencor reports Q1 loss per share $0.31
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Xencor Inc :Xencor reports first quarter 2017 financial results.Q1 loss per share $0.31.Q1 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Xencor Inc - Cash, cash equivalents, and marketable securities totaled $392.7 million as of March 31, 2017, compared to $403.5 million on December 31, 2016.Xencor Inc - Expects to have cash to fund research and development programs and operations beyond end of 2020.Xencor Inc - Expects to end 2017 with approximately $340 million in cash, cash equivalents, and marketable securities.Xencor Inc qtrly revenues $4.3 million versus $7.25 million a year ago.  Full Article

Xencor reports qtrly loss per share $0.21
Tuesday, 28 Feb 2017 04:06pm EST 

Xencor Inc : Qtrly loss per share $0.21 . Based on current operating plans, xencor expects to have cash to fund research and development programs and operations beyond end of 2020 . Xencor expects to end 2017 with approximately $340 million in cash and cash equivalents . Expects to end 2017 with approximately $340 million in cash and cash equivalents . Xencor reports fourth quarter and full year 2016 financial results .Q4 revenue $6.4 million versus i/b/e/s view $5.6 million.  Full Article

Xencor prices public offering of common stock
Thursday, 1 Dec 2016 08:00am EST 

Xencor Inc : Xencor Inc prices public offering of common stock .Says public offering of 4.59 million common shares priced at $24.00 per share.  Full Article

Xencor Inc announces proposed public offering of common stock
Wednesday, 30 Nov 2016 04:01pm EST 

Xencor Inc :Xencor Inc announces proposed public offering of common stock.  Full Article

Xencor q2 earnings per share $1.13
Tuesday, 2 Aug 2016 04:01pm EDT 

Xencor Inc : Q2 earnings per share $1.13 .Q2 revenue $66 million versus $1.0 million.  Full Article

Xencor provides updates on lead programs, reviews bispecific oncology partnership
Tuesday, 28 Jun 2016 07:30am EDT 

Xencor Inc : Xencor provides updates on lead programs and reviews bispecific oncology partnership; announces expansion of bispecific oncology pipeline at analyst day . Announced expansion of its pipeline with two new bispecific oncology programs .Remain on track to initiate Phase 1 trials with subcutaneous formulations of both XMAB5871 and XMAB7195 this year.  Full Article

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS